SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:56S1 • FR0013154002
56S1.DE Key Statistics, Chart & Performance
The current stock price of 56S1.DE is 191.6 EUR. In the past month the price decreased by -7.75%. In the past year, price increased by 11.88%.
56S1.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE turns out to be only a medium performer in the overall market: it outperformed 44.3% of all stocks.
56S1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE. Both the profitability and the financial health of 56S1.DE get a neutral evaluation. Nothing too spectacular is happening here.
56S1.DE Financial Highlights
Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 4.31. The EPS increased by 35.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.98% | ||
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| Debt/Equity | 0.5 |
56S1.DE Forecast & Estimates
18 analysts have analysed 56S1.DE and the average price target is 247.31 EUR. This implies a price increase of 29.08% is expected in the next year compared to the current price of 191.6.
For the next year, analysts expect an EPS growth of 29.12% and a revenue growth 7.45% for 56S1.DE
56S1.DE Ownership
About 56S1.DE
Company Profile
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Company Info
SARTORIUS STEDIM BIOTECH
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
Aubagne PACA FR
Employees: 9961
Phone: 33442845600
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What does SARTORIUS STEDIM BIOTECH do?
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Can you provide the latest stock price for SARTORIUS STEDIM BIOTECH?
The current stock price of 56S1.DE is 191.6 EUR. The price decreased by -3.06% in the last trading session.
Does SARTORIUS STEDIM BIOTECH pay dividends?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.33%. The yearly dividend amount is currently 0.71.
What is the ChartMill rating of SARTORIUS STEDIM BIOTECH stock?
56S1.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in SARTORIUS STEDIM BIOTECH be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 56S1.DE.
Is SARTORIUS STEDIM BIOTECH (56S1.DE) expected to grow?
The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 7.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) will report earnings on 2026-02-03, after the market close.